Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)
Talimogene laherparepvec 和 atezolizumab 在新辅助化疗后 HER2 阴性乳腺癌中的应用:一项机会窗口 II 期试验 (SOLTI-1503 PROMETEO)
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-026-69222-5
Pascual, Tomás; Vidal, Maria; Cejalvo, Juan M; Vega, Estela; Sanfeliu, Esther; Villacampa, Guillermo; Ganau, Sergi; Parreño, Ana María Julve; Zamora, Esther; Miranda, Ignacio; Delgado, Ana; Bermejo, Begoña; Seguí, Elia; Brasó-Maristanty, Fara; de la Cruz-Merino, Luis; Juan, Manel; Galván, Patricia; Gonzàlez-Farré, Xavier; Chillara, Samyukta; Villagrasa, Patricia; Pfefferle, Adam D; O'Connell, Constandina E; Ferrero-Cafiero, Juan M; Oliveira, Mafalda; Perou, Charles M; Prat, Aleix